Foundayo vs Oral Wegovy vs Compounded: How the 3 FDA-Approved and Compounded Oral GLP-1 Options Compare
By mid-2026, anyone who wants an oral GLP-1 has three genuinely different roads to choose from: Foundayo, the FDA-approved Wegovy pill, or a compounded sublingual, drop, or tablet product from a telehealth clinic. They get lumped together in marketing copy as "the pill option," but the evidence behind them — and what you're actually taking — differs enormously.
Head-to-Head
| Foundayo (orforglipron) | Wegovy Pill | Compounded Oral | |
|---|---|---|---|
| FDA status | Approved April 2026 | Approved Dec 22, 2025 | Not FDA-approved |
| Mechanism | Small-molecule GLP-1 agonist | SNAC-enabled peptide (semaglutide) | Varies; mostly no validated absorption tech |
| Dosing rules | Any time, with or without food/water | Empty stomach, ≤ 4oz water, wait 30 min | Varies by provider |
| Trial weight loss | ~11–12% at 72 wks (ATTAIN-1) | ~13.6–16.6% at 64 wks (OASIS 4, two estimands) | No published human trial data |
| Self-pay price | $149–$349/mo by dose | $149/mo+ by plan/dose | $99–$299/mo |
| Insurance path | $25/mo commercial; $50/mo Medicare Part D (from Jul 1, 2026) | Varies by plan | Rarely covered; self-pay |
Foundayo: The New Entrant With a Different Mechanism
Foundayo (orforglipron) is Eli Lilly's oral GLP-1, approved in April 2026 under the FDA's National Priority Voucher program — one of the fastest new-molecule approvals since 2002. It's chemically nothing like semaglutide: a small, non-peptide molecule that only targets the GLP-1 receptor (unlike injectable tirzepatide, which is dual-acting). Because it's small, it doesn't need SNAC or any permeation enhancer, which is why it's the only oral GLP-1 you can take at any time of day, with or without food or water.
In the ATTAIN-1 trial, orforglipron produced roughly 11–12% weight loss at 72 weeks (the exact figure depends on which statistical estimand is cited — Lilly's press materials and the NEJM publication report slightly different numbers for the same data). LillyDirect self-pay pricing scales with dose: $149/mo at the 0.8mg starting dose up to $299–$349/mo at the 5.5–17.2mg range used for meaningful weight loss. Commercially insured patients with coverage often pay around $25/mo, and Medicare Part D coverage at $50/mo began July 1, 2026.
Wegovy Pill: The Established Formula in a New Format
The Wegovy pill uses the same active ingredient and SNAC absorption technology as Rybelsus, but at doses and in a formulation approved specifically for weight management rather than diabetes. In the OASIS trial program, high-dose oral semaglutide produced weight loss broadly comparable to the injectable pen — Novo's own reporting cites 16.6% mean weight loss at 64 weeks among fully adherent OASIS 4 patients, while the treatment-policy estimand in the NEJM abstract is 13.6%. Both numbers describe the same trial; they just count dropouts and non-adherence differently.
The trade-off versus Foundayo is the dosing ritual: Wegovy pill (like Rybelsus) has to be taken on an empty stomach with no more than 4 ounces of water, followed by a 30-minute wait before eating, drinking, or taking other oral medications. Skip that window and absorption drops significantly.
Compounded Oral: The Budget Route With the Least Evidence
Compounded sublingual drops, dissolvable tablets, and gummies are not copies of Foundayo or the Wegovy pill — they're a separate product entirely, prepared by a licensed compounding pharmacy from an individual prescription rather than reviewed and approved by the FDA. Most rely on the theory that a large peptide molecule can absorb through the tissue under the tongue without SNAC or any comparable enhancer. That's a real hypothesis, but it currently lacks published human clinical trial support, and the FDA has been explicit that these formulations are not established as safe or effective at any specific dose.
What compounded oral does offer: lower entry pricing in some cases, no insurance requirement, and continued access for patients who prefer to avoid both needles and the strict dosing windows of the SNAC-based pills.
How to Actually Decide
- Want the most clinical evidence behind your exact dose? Foundayo or the Wegovy pill — both have published Phase 3 data at the doses they're sold at.
- Can't handle the empty-stomach/30-minute rule? Foundayo is the only oral GLP-1 without a dosing-timing requirement.
- No insurance and want the lowest possible monthly cost? Compounded oral semaglutide starts lower than either brand pill — see our full price comparison.
- Specifically want tirzepatide rather than semaglutide? Neither Foundayo nor the Wegovy pill contain tirzepatide — read our oral tirzepatide guide before choosing a compounded route.
Whichever route you're leaning toward, talk to a licensed provider about your specific health history before starting — dosing, drug interactions, and eligibility all vary by individual.